Microbot Medical Reports Increased Q1 Losses and Cash Burn Amidst Initial Product Sales

summarizeSummary

Microbot Medical reported higher Q1 losses and increased cash burn, even as it began generating initial revenues from its robotic system and started selling shares under a new ATM program.

check_boxKey Events

• Increased Net Loss

  Net loss rose to $3.67 million in Q1 2026 from $2.60 million in Q1 2025.

• Higher Operating Cash Burn

  Cash used in operating activities increased to $5.05 million in Q1 2026 from $2.87 million in Q1 2025.

• First Commercial Revenues

  Generated $105,000 in revenue from the LIBERTY Endovascular Robotic System's limited market release.

• ATM Offering Update

  Initiated an At-The-Market offering of up to $39.2 million, with $17,000 in gross proceeds raised as of May 13, 2026.

auto_awesomeAnalysis

Microbot Medical's first-quarter report shows a significant increase in net loss and cash used in operating activities, despite generating initial revenues from its LIBERTY Endovascular Robotic System. The company is ramping up commercialization and continues to burn cash for R&D and sales activities. While management asserts a cash runway of over 12 months, the increased burn rate and the ongoing, albeit slow, utilization of a large At-The-Market offering highlight the need for continued capital.